Medical Developments International Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Medical Developments International ha un patrimonio netto totale di A$45.7M e un debito totale di A$0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente A$59.2M e A$13.4M.

Informazioni chiave

Rapporto debito/patrimonio netto

AU$0

Debito

Indice di copertura degli interessi	n/a
Contanti	AU$9.74m
Patrimonio netto	AU$45.73m
Totale passività	AU$13.43m
Totale attività	AU$59.16m

Aggiornamenti recenti sulla salute finanziaria

Nessun aggiornamento

Recent updates

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( A$26.1M ) di MVP superano le sue passività a breve termine ( A$9.5M ).

Passività a lungo termine: Le attività a breve termine di MVP ( A$26.1M ) superano le sue passività a lungo termine ( A$3.9M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: MVP è esente da debiti.

Riduzione del debito: MVP non ha debiti rispetto a 5 anni fa, quando il suo rapporto debito/patrimonio netto era 0.4%.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: MVP ha una liquidità sufficiente per 8 mesi in base all'ultimo reportfree cash flow, ma da allora ha raccolto ulteriori capitali.

Previsione Cash Runway: Dati insufficienti per determinare se MVP ha una sufficiente pista di cassa se il suo flusso di cassa libero continua a crescere o a ridursi in base ai tassi storici.

Medical Developments International Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Medical Developments International Limited Announces Resignation of Mary Sontrop from the Board, Effective December 20, 2024

Medical Developments International Limited, Annual General Meeting, Oct 24, 2024

Full year 2024 earnings released: AU$0.47 loss per share (vs AU$0.067 loss in FY 2023)

New minor risk - Shareholder dilution

Medical Developments International Limited has filed a Follow-on Equity Offering in the amount of AUD 10.012039 million.

Medical Developments International Limited has filed a Follow-on Equity Offering in the amount of AUD 10.012039 million.

Medical Developments International Limited to Report Q4, 2024 Results on Aug 26, 2024

New minor risk - Profitability

Medical Developments International Limited to Report First Half, 2024 Results on Feb 29, 2024

Medical Developments International Limited, Annual General Meeting, Oct 27, 2023

Full year 2023 earnings released: AU$0.067 loss per share (vs AU$0.17 loss in FY 2022)

Medical Developments International Limited Appoints Russell Basser to the Board Effective 1 September 2023

Medical Developments International Limited to Report Fiscal Year 2023 Results on Aug 31, 2023

New minor risk - Share price stability

First half 2023 earnings released: EPS: AU$0.032 (vs AU$0.10 loss in 1H 2022)

Medical Developments International Limited to Report First Half, 2023 Results on Feb 24, 2023

Medical Developments International Limited Discontinues China Clinical Trials

No independent directors

Medical Developments International Limited Announces Resignation of Max Johnston as Director, Effective 27 October 2022

Medical Developments International Limited, Annual General Meeting, Oct 27, 2022

Full year 2022 earnings released: AU$0.17 loss per share (vs AU$0.18 loss in FY 2021)

Medical Developments International Limited Provides Earnings Guidance for the Fiscal Year 2022 and Revenue Guidance for the Fiscal Year 2023

Medical Developments International Limited to Report Fiscal Year 2022 Results on Aug 26, 2022

Medical Developments International Limited Appoints Tara Eaton as General Counsel and Company Secretary, Effective August 8, 2022

No independent directors

Medical Developments International Limited Announces That US Food and Drug Administration Lifts Clinical Hold on Penthrox

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Medical Developments International Limited to Report Q2, 2022 Results on Feb 24, 2022

Non-Executive Chairman recently bought AU$306k worth of stock

Non-Executive Chairman recently bought AU$1.0m worth of stock

Full year 2021 earnings released: AU$0.18 loss per share (vs AU$0.006 profit in FY 2020)

Medical Developments International Limited Provides Sales Guidance for the Fiscal Year 2022

Medical Developments International Limited Announces Earnings Guidance for the Year Ended June 30, 2021

Non-Executive Chairman recently bought AU$534k worth of stock

Medical Developments International Limited Appoints Mary Sontrop as Non-Executive Director

Revenue misses expectations

First half 2021 earnings released: AU$0.017 loss per share (vs AU$0.004 profit in 1H 2020)

New 90-day low: AU$6.05

New 90-day high: AU$7.13

Medical Developments International Limited Announces Executive Changes

New 90-day high: AU$6.59

Medical Developments International Limited Appoints Brent Macgregor as Chief Executive Officer, Effective November 1, 2020

Medical Developments International Limited Declares No Dividend for the Full Year Ended 30 June 2020

New 90-day low: AU$5.27

New 90-day low - AU$5.51

Full year earnings released

Medical Developments International Limited(ASX:MVP) dropped from S&P/ASX Emerging Companies Index

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Analisi della pista di contanti

Scoprire le aziende sane